These WHO interim recommendations on the use of the Pfizer – BioNTech BNT162b2 vaccine against Covid-19 were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document referenced below.
fir...st issued 8 January 2021, updated 15 June 2021, updated 19 November 2021, updated 21 January 2022, updated 18 August 2022. Available in other languages https://apps.who.int/iris/handle/10665/361720
more
Available in Arabic, Chinese, English, French, Russian and Spanish. You can download a summary of the main report and background documents!
The report demonstrates that the current system—at both national and international levels— was not adequate to protect people from COVID-19. The time it t...ook from the reporting of a cluster of cases of pneumonia of unknown origin in mid-late December 2019 to a Public Health Emergency of International Concern being declared was too long. February 2020 was also a lost month when many more countries could have taken steps to contain the spread of SARS-CoV-2 and forestall the global health, social, and economic catastrophe that continues its grip. The Panel finds that the system as it stands now is clearly unfit to prevent another novel and highly infectious pathogen, which could emerge at any time, from developing into a pandemic.
more
8 February 2021
This document highlights 10 well established Risk Communication and Community Engagement (RCCE) principles that have proven their power. Together they put communities at the heart of the roll out of new vaccines, treatments and tests and promote trust, the critical ingredient for al...l community action. Informed, engaged and empowered communities are the bedrock for the arrival of new vaccines, treatments and tests that will be introduced to reduce the spread of COVID-19 and save lives. With communities fully engaged and actively participating through the full cycle of planning, delivery and assessment for biomedical tools, demand for these tools can be increased, leading to widespread and effective uptake and use
more
31 March 2021
This article is part of a series of explainers on vaccine development and distribution. Learn more about vaccines – from how they work and how they’re made to ensuring safety and equitable access – in WHO’s Vaccines Explained series.
Countries around the world are rolling ou...t COVID-19 vaccines, and a key topic of interest is their safety. Vaccine safety is one of WHO’s highest priorities, and we’re working closely with national authorities to develop and implement standards to ensure that COVID-19 vaccines are safe and effective.
more
Manufacturers:
SK Bioscience Co. Ltd. [COVID-19 Vaccine (ChAdOx1-S [recombinant])]
Serum Institute of India Pvt. Ltd. [COVISHIELD™, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)]
Efficacy shown in clinical trials in participants who received the full series of vaccine (2 doses) ir...respective of interval between the doses was 63.1%, based on a median follow-up of 80 days, but tended to be higher when this interval was longer. The data reviewed at this time support the conclusion that the known and potential benefits of ChAdOx1-S/nCoV-19 [recombinant] vaccine outweigh the known and potential risks.
more
Community Health Volunteers
The assistive technology capacity assessment (ATA-C) is a system-level tool to evaluate a country’s capacity to finance, regulate, procure and provide assistive technology. It can be used for awareness raising, policy and programme design, and ongoing monitoring and evaluation. This manual provide...s guidance and practical information on the ATA-C implementation process. The ATA-C is intended to be implemented by an experienced team, in collaboration with relevant ministries and users’ organizations.
more
The WHO Health Emergencies Programme is currently monitoring 118 events in the region. This week’s main articles cover the following events:
Coronavirus disease 2019 (COVID-19) in Togo
Measles in Chad
Ebola virus disease (EVD) in Équateur Province, Democratic Republic of the Congo.
Forcibly Displaced Myanmar National / Rohingya Refugee Response.
This document gives guidance for medical providers to understand the care of both healthy and COVID suspect or confirmed patients who present for antenatal (ANC), intrapartum (IP), postnatal (PNC), or emergency obstetric and neonatal ...care (EmONC) in the context of caring for the forcibly displaced Myanmar national (FDMN) / Rohingya refugee population.
more
Several countries have demonstrated that COVID-19 transmission from one person to another can be slowed or stopped. This document has been prepared based on the evidence currently available about Coronavirus disease 2019 (COVID-19) transmission (human-to-human transmission primarily via respiratory... droplets from, or direct contact with, an infected person), and is designed to ensure that the accommodation sector can protect the health of its staff and clients.
more
This guideline is based on the current epidemiological knowledge about the COVID-19. India is currently having travel related cases and few cases of local transmission. At this stage, all suspect/ confirmed cases will be isolated in a health care facility. Hence the document is limited in scope to h...ospital deaths.
more
Migrants are less familiar in their new environment in which they temporarily live. They are prone to various social, psychological and emotional trauma in such situations, emanating from fear of neglect by the local community and concerns about wellbeing and safety of their families waiting in thei...r native places. Migrants are forced to leave their native places in search of better opportunities and earnings, sometime leaving behind their families. In many instances, the families in native places depend partially or entirely on the money sent by the migrant earning members of the family.
more
Summary of the Ethopian country office of WHO on COVID-19 activities.
Original Research
Rev Panam Salud Publica 43, 2019 | www.paho.org/journal | https://doi.org/10.26633/RPSP.2019.31
The Kenya Strategic AIDS Framework IV prioritises key populations for interventions
A Manual for Medical Officer
Developed under the Government of India – WHO Collaborative Programme 2008-2009
Accessed: 11.03.2019